Ambrisentan for Treatment of Portopulmonary Hypertension
Status:
Withdrawn
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Portopulmonary hypertension denotes pulmonary hypertension complicating portal hypertension
and is present in approximately 5% of cirrhotic patients. Treatment options include
prostanoids, sildenafil, and the endothelin-receptor antagonists, bosentan and ambrisentan.
This study investigates the safety and efficacy of ambrisentan in portopulmonary
hypertension.